Modified immune cells for pancreatic cancer that has spread
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests a new type of immune therapy for pancreatic cancer. It uses your own immune cells, which are modified in the lab to find and attack cancer cells that have a specific protein called CD318.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have pancreatic cancer that has spread or cannot be removed with surgery, and it must have grown or spread after at least one standard treatment.
- Your tumor must have a specific protein called CD318 (a lab test will confirm this).
- You need to be in fairly good health overall, with a performance status of 0 or 1 (meaning you can do most daily activities).
- You cannot have had CAR T-cell therapy or other gene-modified cell treatments before.
- You must be willing to follow study procedures and attend follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using your own immune cells (called CAR-T cells) that are modified to target a protein called B7-H3 found on pancreatic cancer cells. The goal is to see if this therapy can help shrink or control the cancer.
This trial tests a new treatment using specially engineered immune cells (CAR macrophages) that are designed to find and attack a protein called c-MET on pancreatic cancer cells. It may help people whose cancer has not responded to previous treatments or who could not tolerate them.
This trial tests a new type of immune cell therapy called CAR-NK cells that target two proteins (MSLN and MUC1) often found on pancreatic cancer cells. It is for people whose cancer has spread or cannot be removed, and who have already tried at least one standard treatment.
This trial tests a new type of cell therapy (CAR-T) that targets two markers on pancreatic cancer cells. It's for people with advanced pancreatic cancer who have already tried standard chemotherapy.
This trial tests specially engineered immune cells (CAR-NK cells) designed to find and attack pancreatic cancer cells. The cells target specific proteins on cancer cells and may help people whose cancer has progressed despite prior treatment.
This early-phase trial is testing a new kind of immune cell therapy—dendritic cells and CAR-T cells—that specifically targets a protein called Claudin18.2 on your cancer cells. It is for people with advanced pancreatic cancer who have already tried standard treatments.
Hear when a new Pancreatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.